Expert Interview
Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Ticker(s): GPCR, NVO, LLYInstitution: Columbia University
- Associate Professor of Endocrinology at Columbia University.
- Manages 800 patients with diabetes and 280 patients who are on insulin pumps.
- Research focuses on the role of developmental pathways in the regulation of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease and the use of existing therapeutic agents in other scientific areas in novel applications to ameliorate obesity-induced complications including cancer.
Roughly how many patients with obesity do you manage?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for GSBR-1290?
Added By: ben_adminWill patients prefer an oral weight loss medication that is less efficacious than an injectable medication?
Added By: ben_adminHow do you interpret the high rates of vomiting/nausea seen in Structures phase 2a study?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
